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SUMMARY
What is known and Objective: Studies have
shown that comprehensive interventions by
pharmacists can improve adherence and persis-
tence to osteoporosis therapy, but the association
between adherence and bone turnover markers
(BTMs) has never been studied. Therefore, the
aim of this study was to evaluate the effects of
pharmaceutical care on medication adherence
(and its effects on BTMs), as well as persistence
of postmenopausal osteoporotic women to pre-
scribed bisphosphonates.
Methods: A randomized controlled trial was con-
ducted from 2005 to 2009 in the University Malaya
Medical Centre, Malaysia. Inclusion criteria:
postmenopausal osteoporotic women diagnosed
with osteoporosis with a T-score£)2Æ5 or who had
a low-trauma fracture and prescribed weekly
alendronate ⁄ risedronate. Intervention partici-
pants received counselling on osteoporosis, risk
factors, lifestyle modifications, goals of therapy,
side effects and the importance of adherence.
Adherence was assessed at months 3, 6 and 12,
and persistence at month 12. Feedback on BTMs
was provided at months 4 and 7. The control
group received no counselling. Two BTMs were
used: serum C-terminal cross-linking telopeptide
of type I collagen (CTX-I) and serum osteocalcin
(OC). Main outcomes measured: medication
adherence, BTMs and persistence.
Results and Discussion: Intervention participants
who received pharmaceutical care reported sig-
nificantly higher medication adherence at 6
(P = 0Æ015) and 12 months (P = 0Æ047) compared
with the control group; but this effect was not
shown by the BTMs. This is probably due to
the long effect of bisphosphonates in bone.
A significant difference was found between
serum CTX-I and OC in identifying non-
responders to anti-resorptive therapy (P < 0Æ001),
indicating the usefulness of BTMs as an objec-
tive marker. However, pharmaceutical care did
not affect persistence to osteoporosis therapy
within a 1-year period [log rank (Mantel–Cox)
v2 = 0Æ496, P = 0Æ481]. The proportion of partici-
pants who were persistent with bisphosphonate
therapy after 12 months was 89Æ8% and 87Æ0%
in the control and intervention group respec-
tively.
What is new and Conclusion: The provision of
pharmaceutical care improved medication
adherence but not persistence. BTMs were not
appropriate objective measures for assessing
adherence to weekly bisphosphonates but were
useful for identifying non-responders to treat-
ment within 3–6 months, much earlier than
using bone mineral density. The study indicates
that pharmacists have a role in improving med-
ication adherence, but its long-term effect on
persistence warrants further studies with longer
duration.
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WHAT IS KNOWN AND OBJECTIVE
The ultimate goal of management in osteoporosis is
to prevent fracture, and currently, bisphosphonates
are the drugs of choice (1). However, bisphos-
phonates need to be taken in a specific manner
and for at least a year for evidence of improvement
of bone mineral density (BMD) and protection
against fracture to emerge (2, 3). Approximately
50–75% of women, prescribed anti-osteoporosis
drug therapy, no longer take them 12 months after
initiation of treatment (4). Poor adherence leads to
lower therapeutic efficacy (5, 6), weaker suppres-
sion of bone resorption (7), smaller increases in
BMD (8), less reduction in fracture risk (9) and
drug wastage (6).
By using a multi-faceted approach, physicians,
dietitians, physiotherapists and nurses can suc-
cessfully improve the outcomes of patients with
osteoporosis by monitoring medication adherence
and persistence (10). A systematic review conducted
to assess the effect of such non-drug interventions
on community-dwelling postmenopausal osteopo-
rotic women (11) found three studies that assessed
medication adherence (12–14) and persistence (12,
13, 15) respectively. It was concluded that such
interventions were better in improving adherence
than in improving persistence (66Æ7% vs. 33Æ3%).
Pharmacists are strategically in an excellent
position to provide pharmaceutical care, which is
defined as the responsible provision of drug ther-
apy for the purpose of achieving definite outcomes
that improve quality of life (QOL) (16). Previous
prospective, observational studies showed that
comprehensive interventions by pharmacists
improved adherence to osteoporosis therapy, but
this effect has not been objectively measured using
bone turnover markers (BTMs) (17–19). BTMs,
which reflect the rates of bone turnover, can predict
the risk of osteoporosis-related fractures (20),
assess adherence and effectiveness of osteoporosis
therapy, and detect treatment failure (non-
responders) (21). BTMs are markedly reduced
within 3–6 months of anti-resorptive therapy (22).
If necessary, changes in treatment can be made as
soon as possible, saving almost 2 years of inap-
propriate therapy, as reliable BMD results can only
be obtained after 2 years.
There is little published evidence from random-
ized controlled study of the effects of involvement
of pharmacists in the management of osteoporosis.
Therefore, the primary objective of this study was to
evaluate the effects of pharmaceutical care on
medication adherence and its possible association
with BTMs, as well as persistence of postmeno-
pausal osteoporotic women to their prescribed
bisphosphonates using this study design.
METHODS
This randomized controlled study was conducted
from September 2005 to February 2009 at the Uni-
versity Malaya Medical Centre (UMMC) to assess
adherence (and its effect on BTMs), persistence,
QOL, knowledge and patient satisfaction of post-
menopausal osteoporosis patients. Results on QOL,
knowledge and patient satisfaction will be reported
elsewhere. Approval from the Medical Ethics
Committee, UMMC was obtained before com-
mencement of the study.
Patients
Inclusion criteria. Postmenopausal women who
had just been diagnosed with osteoporosis (BMD
T-score £)2Æ5 ⁄ low-trauma fracture sustained at
‡45 years of age), never on any active osteoporosis
therapy within the past 6 months and just been
prescribed once weekly alendronate (Fosamax,
Merck Sharp & Dohme Corp., Pavia, Italy) or
risedronate (Actonel OSG Norwich Pharmaceu-
ticals, Inc., North Norwich, NY, USA). BTMs are
markedly reduced from baseline to 3 and
6 months later regardless of the type of bis-
phosphonates used. As both alendronate and
risedronate were the most common bisphospho-
nates prescribed in the UMMC (23), patients who
were either on alendronate or risedronate were
included.
Exclusion criteria. Patients with metabolic bone
disease or other medical conditions or treatment
likely to affect bone metabolism, history of chronic
renal, hepatic or gastrointestinal disease or trau-
matic lumbar compression fracture.
Sample size
To detect a mean difference of 5% with a pooled
standard deviation of 10% between the control
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and intervention group, with 80% power of
detection and a = 0Æ05, a sample size of at least
64 was required in each group (24). Assuming a
20% loss to follow up (15), the total number
of participants required was at least 77 in each
arm.
Primary outcomes
Primary outcomes measured were: medication
adherence, BTMs and persistence. Adherence to
bisphosphonate therapy is defined as the average
percentage of participants who were both persis-
tent (continued bisphosphonate therapy) and
compliant (took medication in the correct manner
on the scheduled day) (25).
Research in assessing medication adherence has
been limited by the lack of a true gold standard
(26). Three methods were used to assess medica-
tion adherence: direct-reporting (by asking the
participant, ‘How many doses of the alendro-
nate ⁄ risedronate did you miss since the last time
we met?’), pill count (by counting the number of
bisphosphonate tablets left at each visit) and self-
recording (by asking participants to record the date
they took their bisphosphonates). Persistence
(defined as the time in days from the date of the
first dose of bisphosphonate until discontinuation
of treatment) was obtained from supply records
using the pharmacy information system v8.6
(Ascribe, Bolton, UK).
Two BTMs: serum C-terminal cross-linking
telopeptide of type I collagen (CTX-I), a bone
resorption marker and serum osteocalcin (OC), a
bone formation marker, were assessed so that the
results could be compared and validated. Samples
were collected using standard sampling tubes in
the fasting state (between 8Æ00 and 9Æ00 AM) to
minimize the unpredictable effects of feeding (27)
and measured using electrochemiluminescence
immunoassay (ECLIA) [Elecsys 1010 (serial no:
9003247); Roche Diagnostics, Mannheim, Ger-
many]. Intra-assay variation was 0Æ96–1Æ91% and
1Æ32–2Æ61% for CTX-I (n = 30) and OC (n = 30)
respectively. Inter-assay variation was 1Æ81–2Æ50%
and 5Æ30–6Æ81% for CTX-I and OC respectively.
Six tests were performed for each BTM over a
10-day period. Baseline and follow-up BTMs were
run in the same assay to minimize inter-assay
variation.
PROCEDURE
Potential participants were referred to the
researcher by doctors at the osteoporosis, ortho-
paedic and menopause clinics in the UMMC. All
participants gave their written informed consent
and were provided with a patient information
sheet.
This study used a stratified block randomization
design to ensure that the number of participants on
alendronate and risedronate in the control and
intervention group were the same. Therefore, par-
ticipants were first divided into whether they were
on alendronate or risedronate, then randomly
allocated to the intervention group using the ran-
dom digits table (28) while the rest were allocated
to the control group.
Participants were followed-up over a 12-month
period which involved four visits (Fig. 1). All
participants were dispensed 3 months’ supply of
bisphosphonate and instructed on how to take
their medications. In addition, intervention partic-
ipants received a ‘counselling package’ which
consisted of an explanation on osteoporosis, risk
factors, lifestyle modifications, goals of osteoporo-
sis therapy, side effects and the importance of
medication adherence. Verbal counselling was
reinforced with an osteoporosis booklet. The
pharmacist also reviewed participant’s medica-
tions and conducted monthly follow-up via tele-
phone calls for the first 6 months, then every
3 months until month 12. Control participants
received no counselling.
All participants were requested to record the
date they took their bisphosphonates and to
bring back all remaining medications in their
next visit for a pill count. An independent
research assistant collected the data on medi-
cation adherence to minimize pharmacist inter-
action with control participants and to reduce
intervention bias (29).
To ensure that study participants were a
homogenous cohort with osteoporosis attributed to
menopause, the renal function, full blood count,
thyroid function, calcium, phosphate, alkaline
phosphatase levels, intact parathyroid hormone
(iPTH) and serum 25-hydroxyvitamin D [25(OH)D]
were determined using standard automated clini-
cal laboratory methods in the Central Diagnostic
Laboratory, UMMC (ISO9001:2000 accredited).
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Data analyses
All data were entered into the SPSS version 15 (SPSS,
Chicago, IL, USA). The impact of pharmaceutical
care on medication adherence was analyzed using
non-parametric Mann–Whitney U-test as normality
assumptions could not be fulfilled. Persistence was
analyzed using the Kaplan–Meier survival curve.
The effect of intervention on persistence was
analyzed using an extension of the Cox-regression
model which involved a robust covariance matrix
to adjust for within-cluster correlations (30). Sta-
tistical comparisons were expressed in terms of
discontinuation hazard ratios (HRs). To identify
potential factors that could be associated with
medication adherence, a multiple regression anal-
ysis was conducted.
Changes in BTMs were calculated as differences
between baseline, and at 3 and 6 months, expres-
sed as a percentage of the median of all measure-
ments. Participants who obtained at least a 55% or
40% decrease in CTX-I and OC, respectively, were
considered to have a good BTM response, whereas
participants who showed less than this least
significant change were considered as non-
responders (31). The ability of a BTM to identify
non-responders to bisphosphonate was evaluated
using the McNemar test.
RESULTS AND DISCUSSION
One hundred and ninety-eight patients were
recruited: intervention = 100 and control = 98
(Fig. 2). There was no difference in baseline char-
acteristics between the control and intervention
group (Table 1). The ethnic ratio of participants
was similar to that of patients attending the oste-
oporosis clinic in the UMMC (32).
Medication adherence
In the present study, when medication adherence
was assessed by direct-reporting, no significant
difference was found between the control and
intervention group (Table 2). This method of
assessing medication adherence is easy to perform
but is limited by recall bias of the participants.
Direct-reporting only estimated the number of
doses the patient missed, but did not account for
how missed doses were adjusted.
When adherence was assessed by pill count,
the intervention group showed a significantly
higher adherence at month 6 (P = 0Æ028). How-
ever, the pill count method only revealed
whether the patient took her medication within
that week or month, and not on which particular
day.
BMD=bone mineral density, BTM=bone turnover marker; * At month 4, ** At month 7  
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Fig. 1. Time line of the study. BMD, bone mineral density; BTM, bone turnover marker; *at month 4; **at month 7.
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When adherence was assessed using self-
recording by the participants, adherence at month
6 and 12 was also significantly higher in the inter-
vention group compared with the control group
(P = 0Æ015 and P = 0Æ047 respectively). A high cor-
relation was found between the self-recording and
pill count method (r = 0Æ902–0Æ935, P < 0Æ001)
which is similar to findings by Garber et al. (26)
Therefore, results obtained from the self-recording
method were used for subsequent analyses since
the exact day when the participant took her weekly
medication could be determined.
Absolute adherence to weekly bisphosphonate
therapy is defined as the number of participants
who took their medications exactly on the same day
each week. As no significant difference in absolute
adherence was detected between the control and
intervention group, they were combined for sub-
sequent analysis. Only 99 participants (50%) took
their weekly bisphosphonates exactly as instructed
on the same day each week. However, due to
the unique properties of the bisphosphonates, if
the participant forgot to take her dose on the
designated day of the week and took her missed
dose the next day then returned to taking her dose
on the scheduled day of the week again, she was
still considered as adherent (33). This occurred in
38(38Æ8%) participants in the control group [95%
CI = 29Æ1–48Æ4] and 38(38%) participants in the
intervention group [95% CI = 28Æ5–47Æ5]. Partici-
pants in both the control and intervention group
changed the days on which they took their medi-
cations by up to 5 days (10Æ1%), and some even took
it on different days each week (3Æ0%).
Weekly execution of the dosing regimen among
participants in the control and intervention group
was very similar. Non-adherence to bisphospho-
nates included taking less than the prescribed
amount (43Æ4%) and not taking the medication on
the scheduled day of the week (76Æ8%). The most
common reasons cited for non-adherence were:
forgetfulness (75 participants), busy (33), away
from home (28), avoiding side effects (6) and too
many pills (5). This included participants who
missed their doses but remembered to take them
the following day.
1st visit (month 0) 
Intervention group (n=100)
1st visit (month 0) 
Control group (n=98)
Screened (n=198) 
Adverse events: 3 
Lost to follow-up: 3 
Diagnosed with 
thalassaemia: 1 
Adverse events: 5 
Withdrew consent: 2 
Did not start bisphosphonate 
treatment: 1 
Adverse events: 2 Lost to follow-up: 1 
2nd visit (month 3) 
Control group (n=91)  
2nd visit (month 3) 
Intervention group (n=92) 
3rd visit (month 6) 
Control group (n=90)  
3rd visit (month 6) 
Intervention group (n=90) 
4th visit (month 12) 
Control group (n=89)  
4th visit (month 12) 
Intervention group (n=88) 
Lost to follow-up: 1 Lost to follow-up: 1 
Deceased: 1 
Fig. 2. Summary of the number of participants in the study.
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Persistence
Overall, persistence at 1 year was high and was
similar between the control and intervention
group. Using the log-minus-log plot, the hazards
for the discontinuation of therapy were propor-
tional throughout the study period, and the
Kaplan–Meier survival curve showed no signifi-
cant difference in persistence between the control
and intervention group [log rank (Mantel–Cox)
v2 = 0Æ496, P = 0Æ481]. The proportion of partici-
pants who were persistent with bisphosphonate
therapy after 12 months was 89Æ8% and 87Æ0% in
the control and intervention group respectively.
Those without back pain and those who
consumed alcohol were more likely to drop out
from therapy [hazard ratio (HR) 1Æ53; 95%CI =
1Æ10–2Æ15, P = 0Æ013 and HR 0Æ54; 95%CI = 0Æ35–
0Æ85, P = 0Æ008 respectively]. Nine participants
(4Æ5%) discontinued their bisphosphonates within
the first 3 months of therapy due to adverse
drug effects. These include upper GI adverse
effects (five participants), severe muscle or leg
cramp (three participants) and lethargy (one
participant).
Bone turnover markers
Both serum CTX-I and OC showed a rapid
decrease within the first 3 months of therapy.
Table 1. Baseline characteristics of participants in the intervention study
Characteristics Control (n = 98)
Intervention
(n = 100) bt-value ⁄ v2 P-value
Mean age ± SD (years) [range] 67Æ10 ± 9Æ55 [42–94] 65Æ13 ± 8Æ98 [44–86] 1Æ497 0Æ136
Ethnicity [n (%)]
Malay 17 (17Æ3) 14 (14Æ0) 2Æ642 0Æ450
Chinese 59 (60Æ3) 55 (55Æ0)
Indian and others 22 (22Æ4) 31 (31Æ0)a
Mean BMI ± SD 23Æ59 ± 4Æ20 24Æ04 ± 4Æ57 )0Æ718 0Æ474
BMI range [n (%)]
<18Æ5 (underweight) 9 (9Æ2) 11 (11Æ0) 1Æ464 0Æ691
18Æ5–24Æ9 (normal) 57 (58Æ2) 50 (50Æ0)
25Æ0–29Æ9 (overweight) 25 (25Æ5) 29 (29Æ0)
‡ 30 (obese) 7 (7Æ1) 10 (10Æ0)
Level of education [n (%)]
No formal education 10 (10Æ2) 6 (6Æ0) 2Æ616 0Æ455
Primary education 24 (24Æ5) 19 (19Æ0)
Secondary education 39 (39Æ8) 43 (43Æ0)
Diploma ⁄ tertiary ⁄postgraduate 25 (25Æ5) 32 (32Æ0)
Had a previous fall or fracture [n (%)] 50 (51Æ0) 51 (51Æ0) 1Æ031 0Æ597
No. years menopausal [mean ± SD] 18Æ50 ± 9Æ75 16Æ28 ± 9Æ16 1Æ645 0Æ102
Family history of osteoporosis [n (%)] 15 (15Æ3) 25 (25Æ0) 3Æ392 0Æ183
Alcohol consumption [n (%)]
Occasionally 11 (11Æ2) 14 (14Æ0) 0Æ346 0Æ557
Never 87 (88Æ8) 86 (86Æ0)
Smoking status [n (%)]
Current smoker 2 (2Æ0) 1 (1Æ0)
Ex smoker 2 (2Æ0) 1 (1Æ0) 0Æ730 0Æ694
Never smoked 94 (95Æ9) 98 (98Æ0)
Frequency of exercise [n (%)]
< 3 times ⁄week 50 (51Æ0) 46 (46Æ0) 0Æ480 0Æ286
‡ 3 times ⁄week 48 (49Æ0) 54 (54Æ0)
aOne participant who was classified under ‘others’ was included under the Indian group.
bThe chi-square test was used for all categorical variables whilst the independent t-test was used for all continuous variables.
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However, the change in serum OC was consider-
ably slower compared with the change in serum
CTX-I (Fig. 3a,b). There was no difference in serum
CTX-I and serum OC reduction between the con-
trol and intervention group at months 3 and 6.
Only one non-responder to anti-resorptive therapy
was identified at 6 months. There was significant
difference between the CTX-I and OC in its ability
to detect non-responders at 3 and 6 months
[(McNemar v2 = 33Æ03, P < 0Æ001) and (McNemar
v2 = 9Æ31, P = 0Æ003) respectively].
The present study is one of the first prospective,
randomized controlled trials (RCTs) conducted to
assess the effects of pharmaceutical care on
adherence (and its association with BTMs), as well
as persistence with osteoporosis therapy. Inter-
vention participants who received pharmaceutical
care reported significantly higher medication
adherence compared with the control group, indi-
cating the benefits of providing pharmaceutical
care. However, pharmacist intervention did not
affect persistence to osteoporosis therapy at 1 year
or the BTM of the participants, at up to 6 months.
Bisphosphonates required specific instruction on
timing and how it should be taken (34). This
emphasizes the importance of counselling patients
on the proper method of taking bisphosphonates to
improve adherence. Prompt actions can be taken if
poor adherence or persistence is identified, which
includes reassuring patients about the medication’s
side effects and how to prevent or alleviate the
symptoms of adverse drug reactions and pain.
Due to the long effect of bisphosphonates on the
bone (35), as long as participants take their missed
dose of bisphosphonate within 2 days of the
scheduled day, they can still be defined as adherent
(33). Using this definition, the overall medication
adherence was very good (>95%). However, if
adherence was defined as participants who only
took their weekly dose exactly on the scheduled
day of the week, adherence to weekly bisphos-
phonates was reduced to only 50%, which is
similar to other medication adherence studies with
once-daily dosing (36–38). The two main reasons
for non-adherence to bisphosphonate therapy
were, taking less than was prescribed and changing
the day they took their bisphosphonates (which
resulted in a difference of up to 5 days). Nine
participants (4Æ5%) discontinued their bisphosph-
onates due to adverse drug reactions and pain
attributed to the medication, which was similar to
findings of previous studies (39–41).
The persistence rates with weekly bisphospho-
nates in both the control and intervention group
were higher than expected (89Æ8% and 87Æ0%
respectively). Adherence and persistence tend to be
higher in clinical trials than in real life, especially
when participants in both the control and inter-
vention group have intensive follow-up sessions
(13). Patient motivation may also be higher than in
Table 2. Adherence to once weekly bisphosphonates
Month
Control Intervention Mann–Whitney U-test
Mean ± SD Median Mean ± SD Median Mean rank z-value P-value
Direct-reporting method
No. alendronate ⁄ risedronate
missed since the last visit
3 94Æ96 ± 7Æ01 100Æ00 93Æ21 ± 10Æ26 100Æ00 95Æ18 88Æ86 )0Æ898 0Æ369
6 93Æ98 ± 9Æ92 100Æ00 93Æ24 ± 9Æ17 100Æ00 93Æ82 87Æ18 )0Æ949 0Æ343
12 94Æ27 ± 12Æ27 97Æ92 94Æ73 ± 6Æ56 95Æ83 92Æ45 83Æ49 )1Æ238 0Æ216
Pill count method
3 97Æ30 ± 5Æ35 100Æ00 96Æ57 ± 7Æ23 100Æ00 92Æ82 89Æ20 )0Æ602 0Æ547
6 97Æ01 ± 7Æ22 100Æ00 98Æ83 ± 3Æ02 100Æ00 82Æ64 94Æ49 )2Æ191 0Æ028*
12 96Æ46 ± 10Æ17 100Æ00 97Æ70 ± 4Æ68 100Æ00 84Æ37 90Æ78 )0Æ990 0Æ322
Self-recording method
3 97Æ38 ± 5Æ33 100Æ00 96Æ85 ± 6Æ52 100Æ00 93Æ04 88Æ98 )0Æ683 0Æ495
6 96Æ79 ± 7Æ97 100Æ00 98Æ91 ± 3Æ23 100Æ00 82Æ23 94Æ91 )2Æ426 0Æ015*
12 96Æ17 ± 10Æ95 100Æ00 97Æ97 ± 5Æ25 100Æ00 81Æ70 93Æ57 )1Æ988 0Æ047*
*Statistically significant at P < 0Æ05.
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(a)  Changes in CTX-I in the control and intervention group 
(b)  Changes in OC in the control and intervention group 
Fig. 3. (a) Changes in CTX-I in the control and intervention group. (b) Changes in OC in the control and intervention
group. Results are expressed as the median percentage change from baseline at 3 and 6 months respectively. Using the
Mann–Whitney U-test, no significant difference was detected between the control and intervention group for CTX-I at 3
and 6 months (P = 0.264 and P = 0.372 respectively) as well as for OC at 3 and 6 months (P = 0.709 and P = 0.291
respectively). CTX-I, serum concentration of the C-terminal telopeptide of collagen type I; OC, serum concentration of
osteocalcin; LSC, least significant change.
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actual practice as participants were aware that the
pharmacist was assessing their medication adher-
ence and persistence as one of the primary out-
comes in this study. The situation in real practice
conditions may be different. Therefore, further
observational studies should be conducted to sup-
plement the data obtained from the present RCT in
order to depict a more practice-based scenario.
It was difficult to compare the adherence and
persistence rates between the present study
and other RCTs (12–14), as each study defined and
assessed medication adherence or persistence dif-
ferently. In addition, different studies assessed
adherence and persistence using different medica-
tions (once daily raloxifene ⁄ risedronate vs. once
weekly alendronate ⁄ risedronate). The convenience
of the weekly dosing probably accounts for the
higher adherence and persistence rate in the
present study as compared with previous studies
(12, 13).
There was no significant difference between the
BTMs of the control and intervention participants
in this study at 3 and 6 months. The lack of sig-
nificant correlation may be due to the already high
medication adherence observed in both the control
and intervention group and hence did not affect the
BTMs. In addition, the half-life of bisphosphonates
is very long (1Æ5–10 years) and its serum levels are
only transiently elevated after each dose (42). As a
result, if adherence is interrupted at weekly inter-
vals, most of the active sites will be only a few days
old on an average and relatively little resorption
will occur and hence, this small change will not be
detected by the BTMs. Changes in the BTMs will
only be detected if the patient stops bisphospho-
nate therapy for more than a month (43).
Bone turnover markers monitoring by nurses
improved medication adherence (12), while moni-
toring by physicians did not (13). The differences
could be due to the medication studied (as dis-
cussed earlier) and the methodology used. When
participants were informed of their poor BTM
response, the rate of discontinuance was higher
than those who were informed of a good BTM
response (13). It was not possible to determine this
outcome in the present study as only one partici-
pant had a poor BTM response and was identified
as a non-responder. However, the major advantage
of using a BTM is that by 3 months, non-respond-
ers to therapy can be detected. This is considerably
shorter than the 2 years required for a reliable
BMD test.
The major strength of this study is that it asses-
sed the effectiveness of pharmaceutical care on
medication adherence in postmenopausal osteo-
porotic women. It also attempted to determine any
possible association between medication adherence
and objective measures such as the use of BTMs.
However, one of the limitations in this study is that
data were collected from only one site and hence
cannot be considered as population-based.
WHAT IS NEW AND CONCLUSIONS
The provision of pharmaceutical care improved
medication adherence but not persistence. BTMs
were not appropriate objective measures for
assessing adherence to weekly bisphosphonates
but were useful for identifying non-responders to
treatment within 3–6 months, much earlier than
using BMD. The study indicates that pharmacists
have a role in improving medication adherence,
but its long-term effect on persistence warrants
further studies with longer duration.
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